Banqueiro acionista da Biomm terá assento no conselho da farmacêutica

O banqueiro Daniel Vorcaro, presidente e controlador do Banco Master, é o maior acionista da Biomm, a farmacêutica mineira que disparou 67% na bolsa na última semana após anunciar acordo para trazer um similar do Ozempic ao país a partir de 2026. Na composição acionária da companhia, consta a gestora WNT com a maior posição, com 20,03% do capital – o veículo tem Vorcaro como cotista.

A WNT tem sido a gestora de fundos estratégicos para investimentos do Master e seus sócios e também do empresário Nelson Tanure (Master e Tanure inclusive fecharam mais um negócio juntos na última sexta-feira, vencedores do leilão de privatização da Emae, em São Paulo)

Ogilvy forms health influencer unit to target ‘new frontier’ in marketing

WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation.

People are increasingly turning to TikTok, Instagram and other social media platforms for medical advice and information, partly driven by a lack of direct access to healthcare professionals and a desire for quick solutions.

That is problematic given the amount of contested information and conspiracy theories about medicine and health services that is posted online, for example by members of the “anti-vaccine” movement.

EU approves new antibiotic to tackle rise of superbugs

Pfizer’s Emblaveo to be aimed at some of the most dangerous drug-resistant bacteria

The EU has approved a new antibiotic for serious illnesses such as pneumonia and urinary tract infections, marking a step forward in the drive to combat the growing resistance of “superbugs” to existing drugs.

Emblaveo, marketed in Europe by US pharmaceutical company Pfizer, combines two existing medicines to tackle so-called Gram-negative bacteria that are among the leading drug-resistance threats.